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Introduction: Adenovirus causing severe fatal pneumonia has been well described in infants,
children, and patients with immunocompromised function, but reports in previously healthy
adults are rare. We report 3 cases of severe adenovirus pneumonia in whom conventional me-
chanical ventilation failed and required extracorporeal membrane oxygenation support.
Methods: Retrospective case records review of 3 patients admitted to the medical intensive
care unit, Singapore General Hospital, a tertiary care university-affiliated hospital, with severe
adenovirus pneumonia requiring extracorporeal membrane oxygenation support from February
to March 2013.
Results: All 3 patients were previously healthy immunocompetent adults from the commu-
nity with negative HIV serology. Duration prior to development of respiratory failure
requiring intubation and invasive mechanical ventilation was 2, 8 and 3 days. Veno-
venous extracorporeal membrane oxygenation (ECMO) support as rescue ventilation was
instituted in all 3 patients after 2, 16, and 5 days of conventional mechanical ventilator sup-
port. Duration on ECMO support was 16, 22, and 9 days and mechanical ventilation was 18,
62, and 19 days respectively. Length of stay in intensive care unit was 18, 68, and 21 days,
and length of stay in hospital was 20, 70, and 31 days respectively. Two of the 3 patients
died.of Respiratory and Critical Care Medicine, 20 College Road, Academia, Singapore 169856, Singapore.
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Severe adenovirus pneumonia requiring ECMO support 1811Conclusion: The mainstay of treatment for patients with severe adenovirus pneumonia is
still supportive, with the use of antivirals not apparently effective. Whilst ECMO support
for rescue ventilation may be considered, the outcomes do not appear as promising as other
viral pneumonias, mirroring that previously described in the paediatric population.
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Adenovirus causing severe fatal pneumonia has been well
described in infants, children, and patients with immuno-
compromised function, but reports in previously healthy
adults are rare. We report 3 cases of severe adenovirus
pneumonia in whom conventional mechanical ventilation
failed and required extracorporeal membrane oxygenation
(ECMO) support.
Methods
Retrospective case records review of 3 patients admitted to
the medical intensive care unit, Singapore General Hospi-
tal, a tertiary care university-affiliated hospital, with se-
vere adenovirus pneumonia requiring ECMO support from
February to March 2013. Patients were considered for ECMO
based on a set of criteria used by our centre e age below 65
years, good premorbid status, and presented with a
PaO2:FiO2 ratio <60 secondary to severe pneumonia
despite optimal conventional mechanical ventilation for
over 6 h.
Veno-venous ECMO was performed for all 3 patients.
The common femoral veins were cannulated percutane-
ously using the Seldinger technique. Venous blood was
drained from the inferior vena cava using a long 19 F or
21 F cannula in one common femoral vein and returned to
the venous system via the contralateral femoral vein using
a short 17 F cannula after passing through the oxygenator.
A centrifugal pump was used to drive the circuit flow.
Flow rates were adjusted to achieve adequate
oxygenation.
Results
Age of the 3 patients was 38, 62, and 32 years, and BMI was
21.5, 25.6, and 34.7 kg/m2 respectively. Two were male of
Chinese ethnicity, the third was an Indian female. One of
the 3 patients was a smoker. Duration of symptoms prior to
presentation was 6, 4, and 4 days. Cough and fever were
present in all 3 patients, with a highest temperature of 39,
38.7, and 40 C respectively. One patient had associated
rhinorrhea, another had diarrhoea, and both manifested
rhabdomyolysis. None of the patients presented with
dyspnoea or sorethroat. All 3 patients were previously
healthy immunocompetent adults from the community with
negative HIV serology. Total white cell counts were within
the normal range (4.71, 5.8, and 9.4  109/L) but 2 of the 3
patients manifested mild lymphopenia. Inflammatory
marker CRP was markedly raised although procalcitonin
was only mildly elevated. All 3 patients had adenovirus PCRisolated using the Seegene Anyplex II RV16 Detection Assay
(Seegene, Korea) e 2 from endotracheal tube aspirates and
1 from throat swab. Genotyping revealed adenovirus sero-
type 7 for all 3 patients. Bronchoscopy with bronchial
washings was performed in the 3 patients to exclude any
viral and/or bacterial co-infections and none were detec-
ted. Empiric broad-spectrum antibiotics were initially
administered but deescalated when microbiology results
were available.
Duration prior to development of respiratory failure
requiring intubation and invasive mechanical ventilation
was 2, 8, and 3 days. Veno-venous ECMO support as rescue
ventilation was instituted in all 3 patients after 2, 16, and 5
days of conventional mechanical ventilator support. One
patient required inotropic support prior to ECMO implan-
tation but none were on renal replacement therapy. Dura-
tion on ECMO support was 16, 22, and 9 days and
mechanical ventilation was 18, 62, and 19 days respec-
tively. The 3 patients’ oxygenation response to ECMO is
shown in Table 1.
Two patients were treated with antiviral medications e
one with oseltamivir and the other with cidofovir. Both
patients demised despite maximal support. The third pa-
tient received 3 days of intravenous immunoglobulin and
was discharged home after 31 days in hospital. None of the
patients were given steroid therapy. Length of stay in
intensive care unit was 18, 68, and 21 days, and length of
stay in hospital was 20, 70, and 31 days respectively.
Discussion
Severe adenovirus disease affecting a previously healthy
adult host is rare and reports scarce. Sporadic cases of
severe pneumonia from adenovirus in healthy adults have
been published e serotype 4 [1,2], serotype 7 [3], and more
recently serotype 14 [4]. Outbreaks of severe respiratory
illness caused by adenovirus serotype 14 in the community
[5] and Air Force training facility [6] have also been
described. An older paper described an outbreak in a
mental care centre from serotype 35 [7]. Clinical presen-
tation of our 3 patients were very similar to a previous
review, where cough and high fever were dominant symp-
toms and progression to dyspnoea and acute respiratory
failure occurring within days [8].
Despite the advances in intensive care, overall mor-
tality from severe acute respiratory failure remains high
at 66% [9,10]. Extracorporeal membrane oxygenation was
first clinically introduced in 1972 as a means of cardio-
pulmonary support for patients with potentially reversible
cardiac and/or respiratory failure in whom maximal con-
ventional ventilator strategies have been exhausted. It’s
use is most established in the neonatal and paediatric
Table 1 Oxygenation response to veno-venous extracorporeal membrane oxygenation support.
Pre ECMO D1 D5 D10 D15 Pre ECMO explant Post ECMO explant
Patient 1
ECMO manufacturer/model: Terumo, Capiox SP
Conventional Vent settings FiO2 1.0 1.0 1.0 0.8 1.0
PEEP 12 8 20 18 18
PaO2 50 51 75 52 a
ECMO FiO2 1.0 1.0 0.8 1.0
Patient 2
ECMO manufacturer/model: Maquet, Rotaflow
Conventional Vent settings FiO2 1.0 0.8 0.6 0.7 0.6 0.6 1.0
PEEP 18 12 16 16 16 10 12
PaO2 41 80 93 102 60 57 69
ECMO FiO2 1.0 1.0 1.0 0.6 0.5
Patient 3
ECMO manufacturer/model: Maquet, Rotaflow
Conventional Vent settings FiO2 1.0 0.5 0.6 0.4 0.4 0.5
PEEP 16 8 12 12 12 10
PaO2 51 107 63 70 70 74
ECMO FiO2 1.0 1.0 0.8 0.8
a No blood gas was taken.
1812 S.Y. Low et al.population in whom viral pneumonia accounts for 25% of
all respiratory failure cases necessitating ECMO with an
overall survival of 60% [11]. Unfortunately a primary
diagnosis of adenovirus pneumonia often requires pro-
longed ECMO support and portends the poorest survival of
25% [12]. The use of ECMO in adult respiratory failure is
more controversial with previous randomized controlled
studies failing to demonstrate an improved outcome with
ECMO support [13,14]. More recent studies have suggested
that careful patient selection is crucial to outcome, with
isolated viral pneumonia demonstrating the highest sur-
vival rates of 78% with ECMO [15,16]. The H1N1 influenza
pandemic led to a resurgence of interest in the feasibility
of adult ECMO support with studies showing an overall in-
hospital mortality of 28% [17]. We could find only one
previous publication of ECMO support for severe adeno-
virus pneumonia in an adult heart transplant recipient
[18]. Our report suggest that ECMO support for rescue
ventilation in patients with severe adenovirus pneumonia
may improve outcome, although overall mortality remains
high.
Conclusion
More than 40 years after the first description of adenovirus
serotype 7 causing fatal pneumonia in 3 healthy military
trainees [3], we report 3 previously healthy adults with
severe adenovirus serotype 7 pneumonia in whom conven-
tional mechanical ventilation failed and required ECMO
support. The mainstay of treatment is still supportive, with
the use of antivirals not apparently effective. Despite the
advances in intensive care, 2 of our 3 patients died. Whilst
ECMO support for rescue ventilation may be considered for
patients with severe adenovirus pneumonia, the outcomes
do not appear as promising as other viral pneumonias,
mirroring that previously described in the paediatric pop-
ulation [12].Acknowledgement
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